Antibiotic Resistance News and Research

RSS

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

Incidence of KPC-producing bacteria is rising in Chicago

In a survey of Chicago-area healthcare facilities, researchers at Rush University Medical Center and the Cook County Department of Public Health have found that the incidence of KPC-producing bacteria is rising. These bugs cause infections with high mortality rates and are resistant to the most commonly used antibiotics.

25 Oct 2010

UTHSC-Houston initiates enrollment in NanoLogix technology trial for detection of GBS in pregnant women

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today that the University of Texas Health Science Center in Houston is enrolling 300 patients in an ongoing clinical trial to study the speed and accuracy of NanoLogix technology. The trial is designed to compare NanoLogix technology to current methods in use for detection and identification of Group B Streptococcus (GBS) in pregnant women.

20 Oct 2010

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA).

15 Oct 2010

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

The Associated Press reports that global prescription drug sales should rise 5 percent to 7 percent next year reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

8 Oct 2010

First Edition: October 7, 2010

Today's headlines include stories on waivers given some companies that offer only minimal health insurance coverage, insurers' political efforts during this campaign season and efforts in New York to bar the use of food stamps to buy soda.

7 Oct 2010

Study on resistance of harmful bacteria to antibiotics

A study by two Florida State University biochemists makes an important contribution to science's understanding of a serious problem causing concern worldwide: the growing resistance of some harmful bacteria to the drugs that were intended to kill them.

6 Oct 2010

Data shows Take Care Clinics’ quality of care exceeds national benchmarks

Take Care Health Systems, a wholly-owned subsidiary of Walgreens and the nation's largest and most comprehensive manager of convenient care clinics and worksite health and wellness centers, today announced that an analysis of de-identified data collected through the company's electronic medical record (EMR) system by the Jefferson School of Population Health showed that the quality of care delivered in Take Care Clinics for treatment of pharyngitis (inflammation of the throat) and upper respiratory infections (URI) meets or exceeds the quality of the care delivered in other settings.

5 Oct 2010

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

A UC Irvine infectious disease specialist has received a three-year, $10 million grant to explore the effectiveness of new methods to prevent staph infections in people who harbor MRSA bacteria when they're discharged from the hospital.

4 Oct 2010

Food labeling urged to be more stringent

After recent research from campaigning organization Greenpeace found the S-26 Soy brand of infant formula contains GM or genetically modified ingredients that are not disclosed on the product label, two Senators are urging the Federal Government to tighten Australia's food labeling laws.

30 Sep 2010

Researchers identify mechanism that makes bacteria to resist antibiotics

A research team led by Edward Yu of Iowa State University and the Ames Laboratory has discovered the crystal structures of pumps that remove heavy metal toxins from bacteria, making them resistant to antibiotics.

24 Sep 2010

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.

14 Sep 2010

Experts warn dip in antibiotic R&D could lead to treatment challenges

The 50th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) kicked off in Boston on Sunday with experts warning that a "slowdown" in research on antibiotic development could result in treatment challenges.

14 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Concerted action on antibiotic resistance discussed at Uppsala meeting

For 70 years the world has mismanaged the common good of antibiotics. The result is a growing global burden of antibiotic resistance, threatening to take health care back to an era where ordinary infections might once again become fatal.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA.

8 Sep 2010

Scientists urge government to set target effectiveness for newly approved antibiotics

The United States must focus on conserving the use of antibacterial drugs, or face a public health crisis from rapidly rising rates of antibiotic-resistant infections, according to an analysis out today.

7 Sep 2010

BARDA awards $27 million contract to Achaogen for antibiotic development

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a contract to develop an antibiotic that could be used against possibly two types of bioterrorism as well as common infections that are becoming resistant to antibiotics.

31 Aug 2010